Protagen Diagnostics

Protagen is the leading specialist in the development of novel in-vitro diagnostic (IVD) tests, patient stratification tools and companion diagnostics (CDx) in the fields of immuno-oncology and autoimmune diseases. With a best-in-class IP portfolio, the company combines its extensive expertise in autoantigen and autoantibody profiling with proprietary technology platforms to detect disease-relevant biomarkers, identify novel therapeutic targets and develop new diagnostic tools.

Autoimmune Diagnostic Assays

Protagen's unique autoantibody screening technologies and biological repositories support the identification of novel, exclusive, disease-specific biomarkers for the development of new IVD assays. Focusing on a number of diseases with an unmet need, Protagen’s aim is to augment current tools to improve the diagnosis and management of diseases such as RA, SSc, and SLE. New tests will allow clinicians and researchers to better differentiate between autoimmune diseases and recognize specific disease states earlier during disease onset, while also enabling more targeted and effective treatment regimens. The Multilisa SSc program includes the first of a number of new CE-approved IVD tests, Multilisa BICD2, CENP-B and Scl-70, in the pipeline. Protagen also has a number of other test programs on the horizon including Multilisa RA and SLE.

Autoimmune Patient Stratification

The ability to stratify patients into different disease subgroups based on the individual molecular characteristics of each subtype can drive better drug development and improve the success rate of clinical trials. To this end, Protagen’s NavigAID companion diagnostic concept has been designed to better stratify patients suffering with autoimmune diseases. NavigAID SLE the first to be made available so far. The NavigAID stratification tool enables differential diagnosis, better disease activity assessment and improved response prediction. Protagen has a number of other NavigAID products in the pipeline including NavigAID SSc, RA and SjS.

News

Protagen Inks License Agreement with Inova Diagnostics for its proprietary BICD2 Biomarker

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, and Inova Diagnostics, a global leader in the development and commercialization of in-vitro diagnostic systems and reagents for autoimmune diseases, have signed a semi-exclusive license agreement for BICD2, a novel autoantigen and the first proprietary biomarker discovered by Protagen employing its SeroTag® technology.

Protagen AG Appoints Bernhard Kirschbaum as New Chairman and Oliver Schacht as New Board Member

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that Dr. Oliver Schacht, CEO of Curetis N.V., Holzgerlingen, has joined the company's Supervisory Board. Additionally, Dr. Bernhard Kirschbaum, former Merck Pharma Executive and member of the Protagen Board since 2015, was elected as the new Chairman, taking over the position from Prof. Dr. Axel Kleemann.

Protagen announces CE Mark for its proprietary Multilisa® BICD2 test for better diagnosis of Systemic Sclerosis

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today announced that it gained CE marking for the Multilisa® BICD2 test. BICD2 is the first proprietary biomarker discovered by Protagen employing the SeroTag® technology platform, and provides significant added value to standard diagnostics for Systemic Sclerosis (SSc).